START with immunogenicity1‑3

FluMist Quadrivalent provides immunogenicity against an additional strain of influenza B1‑3

  • When studied, the additional B strain in FluMist Quadrivalent did not cause immune interference with other strains contained in the vaccine1‑3
FLUMIST QUADRIVALENT DEMONSTRATED COMPARABLE IMMUNOGENICITY TO BOTH THE YAMAGATA AND THE VICTORIA FORMULATIONS OF TRIVALENT FLUMIST IN THOSE STRAINS STUDIED IN CHILDREN AND ADULTS AGED 2 TO 491‑3
FluMist® Quadrivalent – HAI Geometric Mean Titer Ratios
FluMist Quadrivalent helps provide 4-strain coverage without resulting in immune interference to other strains included in the vaccine1‑3

Contraindications

  • Previous severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine
  • Concomitant or aspirin-containing therapy in children and adolescents 2 through 17 years of age

Warnings/Precautions/Groups/
Conditions

  • Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following administration of FluMist Quadrivalent. FluMist Quadrivalent has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FluMist Quadrivalent should be based on careful consideration of potential benefits and risks
  • FluMist Quadrivalent has not been studied in immunocompromised persons
  • Safety has not been established in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications
  • If pregnant or nursing: There have been no adequate and well-controlled studies in pregnant women. It is not known if FluMist Quadrivalent is excreted in human milk

START with a safety profile comparable to trivalent FluMist1

FluMist Quadrivalent helps provide additional coverage without compromising safety and tolerability1

FluMist® Quadrivalent

FluMist Quadrivalent is built on the foundation of trivalent FluMist.
Click below to see clinical data for FluMist.

Important Safety Information

FluMist®Quadrivalent is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist® (Influenza Vaccine Live, Intranasal).

Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FluMist®Quadrivalent administration. FluMist®Quadrivalent has not been studied in persons with severe asthma or active wheezing.

If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FluMist®Quadrivalent should be based on careful consideration of the potential benefits and risks.

FluMist®Quadrivalent has not been studied in immunocompromised persons.

The safety of FluMist®Quadrivalent in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established.

FluMist®Quadrivalent may not protect all individuals receiving the vaccine.

The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FluMist were runny nose or nasal congestion in all persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FluMist®Quadrivalent, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FluMist®Quadrivalent, 44% reported runny nose or nasal congestion and 19% reported sore throat.

INDICATION

FluMist®Quadrivalent (Influenza Vaccine Live, Intranasal) is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist®Quadrivalent is for intranasal administration only.

Please see full Prescribing Information for FluMist®Quadrivalent, including Patient Information.